<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04273776</url>
  </required_header>
  <id_info>
    <org_study_id>WRAIR #2492</org_study_id>
    <nct_id>NCT04273776</nct_id>
  </id_info>
  <brief_title>A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study</brief_title>
  <official_title>A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Reed Army Institute of Research (WRAIR)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate two pharmacotherapeutic approaches to&#xD;
      sleep induction, both of which have been shown to be effective hypnotics, but may have unique&#xD;
      side effect profiles. These profiles may have markedly different impacts on performance in a&#xD;
      military setting. In this randomized, double-blind, placebo controlled study, the side&#xD;
      effects of these drugs will be compared - suvorexant, a dual orexin receptor antagonist and&#xD;
      zolpidem, a non-benzodiazepine gamma-aminobutyric acid (GABA) A agonist - in healthy controls&#xD;
      comparable in age and gender to the target military population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">November 13, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Randomization will occur at the level of the study session such that all volunteers participating in the same session will be &quot;blocked&quot; together (i.e., assigned the same condition).</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Study sessions will be randomized prior to the study (e.g. Session 1 = placebo, Session 2 = zolpidem, etc.) and volunteers will be assigned a session (treatment group) when they are scheduled for their enrollment visit (Day 1). The randomization schedule will be generated using a random number generator by a person who is not involved in data collection prior to commencement of the study, with the following qualification (hence &quot;pseudo-random&quot;): that all volunteers participating in the same session be randomized or &quot;blocked&quot; together (i.e., assigned the same condition). This will help ensure double-blinding since it may be obvious to volunteers and staff within the same session if some volunteers receive placebo whereas others receive active drug. To help maintain confidentiality, each participant will also be given a unique numerical identifier (e.g., 01-120).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>consolidation of episodic memory</measure>
    <time_frame>5 days</time_frame>
    <description>presentation of word lists</description>
  </primary_outcome>
  <primary_outcome>
    <measure>psychomotor vigilance test</measure>
    <time_frame>4 days</time_frame>
    <description>measures reaction time</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Performance Enhancing Product Use</condition>
  <arm_group>
    <arm_group_label>Suvorexant Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg of Suvorexant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zolpidem Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg of Zolpidem</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10mg of Avicel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant 10 mg</intervention_name>
    <description>10 mg of suvorexant</description>
    <arm_group_label>Suvorexant Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem</intervention_name>
    <description>5 mg of zolpidem</description>
    <arm_group_label>Zolpidem Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Avicel</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Suvorexant Arm</arm_group_label>
    <arm_group_label>Zolpidem Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Healthy males and non-pregnant, non-lactating female volunteers must be between the ages of&#xD;
        18 and 39&#xD;
&#xD;
          -  learned English as a first language (inclusive)*.&#xD;
&#xD;
          -  To be included in the study, volunteers will have to pass a &quot;Volunteer Comprehension&#xD;
             Assessment&quot; with a score of 80% or greater. A maximum of two attempts is permitted.&#xD;
             See section 5.7 for details.&#xD;
&#xD;
          -  Females of child-bearing potential must be on some form of birth control, if sexually&#xD;
             active (e.g., oral contraceptive, condom, intrauterine device, etc.)&#xD;
&#xD;
               -  Volunteers must have learned English as their first language. This is because&#xD;
                  there are cognitive tests administered during the study that require a mastery of&#xD;
                  the English language.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Self-reported habitual nightly sleep amounts outside the target range of approximately&#xD;
             6-9 hours (i.e., less than 6 hours per night or more than 9 hours per night, on&#xD;
             average) (Post-consent Checklist).&#xD;
&#xD;
          -  Any use of prescription or over-the-counter sleep aids during the 3-month period prior&#xD;
             to screening determined by the examining study medical investigator to be indicative&#xD;
             of a potential sleep disorder (e.g., use of a sleep aid for several nights following&#xD;
             travel across multiple time zones would not necessarily constitute evidence of a sleep&#xD;
             disorder).&#xD;
&#xD;
          -  Self-reported nighttime lights-out times earlier than 2000 or later than 0100 during&#xD;
             weeknights (Sunday through Thursday) (Post-consent Checklist)&#xD;
&#xD;
          -  Self-reported morning wake-up times earlier than 0500 or later than 0900 during&#xD;
             weekdays (Monday through Friday) (Post-consent Checklist)&#xD;
&#xD;
          -  Self-reported habitual napping (&gt; 3 times a week) in conjunction with normal sleep&#xD;
             habits (Post-consent Checklist).&#xD;
&#xD;
          -  Self-reported symptoms suggestive of a sleep disorder (including but not limited to&#xD;
             insomnia, narcolepsy, sleep disordered breathing/sleep apnea, idiopathic hypersomnia,&#xD;
             restless leg syndrome, parasomnias, REM behavior disorder, etc.) (Post-Consent&#xD;
             Checklist, Medical History/Exam form; Berlin Questionnaire); history of a sleep&#xD;
             disorder (Medical History and Examination) or evidence of such from a prior&#xD;
             polysomnographic assessment.&#xD;
&#xD;
          -  Objective evidence of narcolepsy + cataplexy using the Ullanlinna Narcolepsy Scale&#xD;
&#xD;
          -  Objective evidence of insomnia using the Insomnia Severity Index.&#xD;
&#xD;
          -  STATE TRAIT ANXIETY INVENTORY - TRAIT (STAI-T) - Scores above 40.&#xD;
&#xD;
          -  MORNING-EVENINGNESS QUESTIONNAIRE -Scores lower than 31 or greater than 69.&#xD;
&#xD;
          -  Self-reported caffeine use in excess of 400 mg (e.g., approximately 8 caffeinated&#xD;
             sodas or approximately 20 ounces of brewed coffee) per day on average (Post-consent&#xD;
             Checklist)&#xD;
&#xD;
          -  History of neurologic disorder (including but not limited to epilepsy or another&#xD;
             seizure disorder, amnesia, hydrocephalus, Parkinson's disease, MS) (Medical History&#xD;
             and Examination form). An infrequent or resolved single neurological event (e.g.,&#xD;
             childhood seizure, rare sporadic migraine headaches, resolved meningeal infection with&#xD;
             no sequelae) may be deemed non-exclusionary at the discretion of the examining study&#xD;
             medical investigator.&#xD;
&#xD;
          -  Score of 14 or above on the Beck Depression Inventory (BDI form)&#xD;
&#xD;
          -  History of cardiovascular disease (including but not limited to arrhythmias, valvular&#xD;
             heart disease, congestive heart failure, history of myocardial infarction) (Medical&#xD;
             History/Exam form)&#xD;
&#xD;
          -  Underlying acute or chronic pulmonary disease requiring daily inhaler use (Medical&#xD;
             History /Exam form)&#xD;
&#xD;
          -  Kidney disease or significant kidney abnormalities (Medical History/Exam form,&#xD;
             laboratory results) as determined by examining study medical investigator.&#xD;
&#xD;
          -  Liver disease or significant liver abnormalities (Medical History/Exam form,&#xD;
             laboratory results) as determined by examining study medical investigator.&#xD;
&#xD;
          -  Self-reported history of psychiatric disorder requiring hospitalization or psychiatric&#xD;
             medication for more than 6 months (Medical History/Exam form)&#xD;
&#xD;
          -  Self-reported or suspected use of products or drugs that cannot be safely discontinued&#xD;
             during in-laboratory phases, to be determined on a case-by-case basis by the examining&#xD;
             study medical investigator (Medical History/Exam form).&#xD;
&#xD;
          -  Self-reported or suspected heavy alcohol use (minimum limit to define heavy alcohol&#xD;
             use is 14 drinks per week or as determined by the examining study medical&#xD;
             investigator).&#xD;
&#xD;
          -  Self-reported or suspected regular nicotine use (or addiction) (defined as more than 1&#xD;
             cigarette or equivalent per week) within the last 1 year.&#xD;
&#xD;
          -  Self-reported or suspected current use of other illicit drugs (including but not&#xD;
             limited to benzodiazepines, amphetamines, cocaine, marijuana) (Medical History/Exam&#xD;
             form)&#xD;
&#xD;
        Positive urine pregnancy result&#xD;
&#xD;
          -  Positive salivary alcohol screening result&#xD;
&#xD;
          -  Self-reported or suspected current breast-feeding or collecting breast-milk (Medical&#xD;
             History/Exam form)&#xD;
&#xD;
          -  Resting blood pressure above 140/90 or resting pulse &gt; 110 beats per minute (Medical&#xD;
             History/Exam form) Note that if a repeat measurement is within range, volunteer will&#xD;
             not be excluded.&#xD;
&#xD;
          -  BMI â‰¥ 30 (Obese Class I or greater) (Medical History/Exam form)&#xD;
&#xD;
          -  Clinically significant values (as determined by the reviewing study medical&#xD;
             investigator and the table below) for any hematology or chemistry parameter included&#xD;
             in the screening bloodwork.&#xD;
&#xD;
          -  Positive urine nicotine/cotinine result during screening visit (NicCheckTM I test&#xD;
             strip results)&#xD;
&#xD;
          -  Positive urine drug screen result&#xD;
&#xD;
          -  Inability to read and sign consent&#xD;
&#xD;
          -  Failure to obtain required approved official leave to participate&#xD;
&#xD;
          -  Presence of features that may increase risk and/or discomfort during the cold pressor&#xD;
             task. These include: past cramp attacks or blackouts, chilblains, open skin wounds,&#xD;
             fracture of the hands, and skin and peripheral vascular diseases (to include but not&#xD;
             limited to Raynaud's disease.&#xD;
&#xD;
          -  As prisoners will not be recruited and are not eligible for participation in this&#xD;
             study, any participant that becomes incarcerated during Phase 1 will result in&#xD;
             termination from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

